MOR - MorphoSys reports positive Phase 3 results for myelofibrosis drug candidate
2023-11-20 17:12:31 ET
More on MorphoSys
- MorphoSys: Buying Constellation Was A Desperate Measure
- MorphoSys: Still Positive Moving Into Pelabresib Data (Maintaining Buy Rating)
- MorphoSys AG 2023 Q3 - Results - Earnings Call Presentation
- I-Mab gains FDA breakthrough tag for kidney disease therapy
- MorphoSys expects a 5% surge in Monjuvi sales for Q3
For further details see:
MorphoSys reports positive Phase 3 results for myelofibrosis drug candidate